Literature DB >> 35751670

Pelvic floor symptoms in cisgender women with Ehlers-Danlos syndrome: an international survey study.

Olga Kciuk1, Qixuan Li2, Ella Huszti2, Colleen D McDermott3.   

Abstract

INTRODUCTION AND HYPOTHESIS: Ehlers-Danlos Syndrome (EDS) is a group of inherited connective tissue disorders associated with abnormal collagen, and is more prevalent in women than in men. The aim of this cross-sectional study was to characterize pelvic floor symptoms in cisgender women with EDS and to describe their impact on quality of life.
METHODS: An online questionnaire on obstetric and gynecological experiences of cisgender women with EDS was disseminated through EDS patient societies and social media. This study was a sub-analysis of the broader questionnaire and focused on pelvic floor disorders, whereby self-reported symptoms and validated questionnaires were used to assess pelvic floor symptom severity (Pelvic Floor Distress Inventory, PFDI-20), impact on quality of life (Pelvic Floor Impact Questionnaire, PFIQ-7), and sexual function (Female Sexual Function Index, FSFI-6). Groups based on age and EDS type were compared using Kruskal-Wallis and Chi-squared tests.
RESULTS: A total of 1,303 participants were included in the analysis. Pelvic floor symptom prevalence included: stress urinary incontinence in 60%, urgency urinary incontinence in 54%, fecal incontinence in 24%, and pelvic organ prolapse in 21%. Bladder symptoms were reported to be the most bothersome. The impact of prolapse symptoms on quality of life was higher in women under age 40 than in older participants (p<0.001). Pelvic pain was reported in 71%. Pain ratings were highest for dysmenorrhea, muscle and joint pain, and backache (median 7 out of 10 for each). Almost half of participants screened positive for possible sexual dysfunction and 36% reported dyspareunia more than half the time.
CONCLUSIONS: This large, observational study demonstrated that cisgender women with EDS report a high prevalence of pelvic floor symptoms that appear to be more severe than in the general population.
© 2022. The International Urogynecological Association.

Entities:  

Keywords:  Ehlers–Danlos syndrome; Fecal incontinence; Pelvic floor symptoms; Pelvic organ prolapse; Pelvic pain; Urinary incontinence

Year:  2022        PMID: 35751670     DOI: 10.1007/s00192-022-05273-8

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  25 in total

1.  Prevalence of Functional GI Diseases and Pelvic Floor Symptoms in Marfan Syndrome and Ehlers-Danlos Syndrome: A National Cohort Study.

Authors:  Judy Nee; Saikiran Kilaru; John Kelley; Sveta S Oza; William Hirsch; Sarah Ballou; Anthony Lembo; Jacqueline Wolf
Journal:  J Clin Gastroenterol       Date:  2019-10       Impact factor: 3.062

2.  Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients.

Authors:  Marco Castori; Filippo Camerota; Claudia Celletti; Chiara Danese; Valter Santilli; Vincenzo Maria Saraceni; Paola Grammatico
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

3.  Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic.

Authors:  A D Nelson; M A Mouchli; N Valentin; D Deyle; P Pichurin; A Acosta; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2015-09-16       Impact factor: 3.598

4.  Urinary incontinence and pelvic organ prolapse in women with Marfan or Ehlers Danlos syndrome.

Authors:  M E Carley; J Schaffer
Journal:  Am J Obstet Gynecol       Date:  2000-05       Impact factor: 8.661

5.  Gynecologic disorders in women with Ehlers-Danlos syndrome.

Authors:  L J McIntosh; V T Mallett; J D Frahm; D A Richardson; M I Evans
Journal:  J Soc Gynecol Investig       Date:  1995 May-Jun

6.  The 2017 international classification of the Ehlers-Danlos syndromes.

Authors:  Fransiska Malfait; Clair Francomano; Peter Byers; John Belmont; Britta Berglund; James Black; Lara Bloom; Jessica M Bowen; Angela F Brady; Nigel P Burrows; Marco Castori; Helen Cohen; Marina Colombi; Serwet Demirdas; Julie De Backer; Anne De Paepe; Sylvie Fournel-Gigleux; Michael Frank; Neeti Ghali; Cecilia Giunta; Rodney Grahame; Alan Hakim; Xavier Jeunemaitre; Diana Johnson; Birgit Juul-Kristensen; Ines Kapferer-Seebacher; Hanadi Kazkaz; Tomoki Kosho; Mark E Lavallee; Howard Levy; Roberto Mendoza-Londono; Melanie Pepin; F Michael Pope; Eyal Reinstein; Leema Robert; Marianne Rohrbach; Lynn Sanders; Glenda J Sobey; Tim Van Damme; Anthony Vandersteen; Caroline van Mourik; Nicol Voermans; Nigel Wheeldon; Johannes Zschocke; Brad Tinkle
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-03       Impact factor: 3.908

7.  Obstetric and gynecologic challenges in women with Ehlers-Danlos syndrome.

Authors:  Bradley S Hurst; Sara S Lange; Susan M Kullstam; Rebecca S Usadi; Michelle L Matthews; Paul B Marshburn; Megan A Templin; Kathryn S Merriam
Journal:  Obstet Gynecol       Date:  2014-03       Impact factor: 7.661

8.  High rate of dyspareunia and probable vulvodynia in Ehlers-Danlos syndromes and hypermobility spectrum disorders: An online survey.

Authors:  Jennifer E Glayzer; Barbara L McFarlin; Marco Castori; Marie L Suarez; Monya C Meinel; William H Kobak; Alana D Steffen; Judith M Schlaeger
Journal:  Am J Med Genet C Semin Med Genet       Date:  2021-11-07       Impact factor: 3.359

9.  Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type ehlers-danlos syndrome: a cohort study.

Authors:  Justine Hugon-Rodin; Géraldine Lebègue; Stéphanie Becourt; Claude Hamonet; Anne Gompel
Journal:  Orphanet J Rare Dis       Date:  2016-09-13       Impact factor: 4.123

10.  Prevalence and Predictors of Gastrointestinal Dysmotility in Patients with Hypermobile Ehlers-Danlos Syndrome: A Tertiary Care Center Experience.

Authors:  Mohammad Alomari; Asif Hitawala; Pravallika Chadalavada; Fahrettin Covut; Laith Al Momani; Shrouq Khazaaleh; Falgun Gosai; Suleiman Al Ashi; Ashraf Abushahin; Alison Schneider
Journal:  Cureus       Date:  2020-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.